In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications.The proposed ...

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has accepted for review a Biologics License Application for AVT06, a proposed biosimilar to Eylea® (aflibercept), which treats eye ...

Zacks Investment Research Image Source: Zacks Investment Research ADMA’s supplemental biologics license applications (sBLAs) for both Asceniv and Bivigam were approved by the FDA last year.